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Abstract
Background: The histological evaluation of estrogen receptor (ER) and progesterone
receptor (PR) expression in breast cancer lesions from biopsy tissue can stratify patients
to receive endocrine therapy. Furthermore, PR expression can predict response
to selective estrogen receptor modulators (SERMs). Current immunohistochemical
approaches to PR detection are limited by sampling error associated with biopsy
and lack of standardised protocols; positron emission tomography (PET) using
receptor targeted radiopharmaceuticals to provide quantitative, whole-body
imaging may overcome these limitations. PR expression has been successfully
imaged with PET in the clinical setting, however investigation into new radioligands
with improved pharmacokinetics and metabolic stability is desirable.
Results: We report the synthesis of a focused library of non-steroidal PR ligands
evaluated for use as PET radioligands. A lead candidate ([18F]2) with low nanomolar
activity was selected and radiolabelled with a radiochemical yield of 2.29 ± 2.31%
(decay-corrected), radiochemical purity (RCP) > 95% and a molar activity of 2.5 ± 1.6
GBq/μmol. Cell uptake studies showed a significant and specific accumulation of [18F]2
in T47D (PR++) breast cancer cell compared to MDA-MB-231 (PR-) control; however, in
vivo evaluation was confounded by rapid defluorination of the radioligand. In vitro
metabolite analysis of 2 in MLM confirmed defluorination and oxidative metabolism of
the thiocarbamate to oxocarbamate moiety by mass spectrometry.
Conclusions: A route to access [18F]2 was developed to allow in vitro and in vivo
evaluation, albeit with low radiochemical yield and modest molar activity. [18F]2
demonstrated selective uptake in PR++ T47D cells which could be blocked in a
dose dependent manner with progesterone. However, [18F]2 showed poor in vivo
metabolic stability with rapid defluorination within the time frame of the imaging
protocol.
Keywords: PET, Fluorine-18, Progesterone, Steroid hormone receptor, Tanaproget,
Fluoropyridine metabolism
Background
The steroid hormone receptor (SHR) family includes estrogen receptors (ERs), progester-
one receptors (PRs) and androgen receptors (ARs) all of which have been studied using
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molecular imaging in cancer of the breast, endometrium and prostate (Mcguire, 1978, Su-
zuki et al., 2003). In most patients, ER-associated proliferative signalling is maintained by
endogenous estradiol binding in the ER ligand-binding domain (LBD). Targeting ER with
selective estrogen receptor modulators (SERMs) is a successful therapy in breast cancer
for patients who express functioning ER (Osborne, 1998). The current standard of care af-
fords the stratification of patients into potential responders/non-responders to endocrine
therapy from histological evaluation of ER/PR expression in tissue from a primary lesion
using a core-needle biopsy (Harvey et al., 1999, Osborne et al., 1980). The expression of
PR can be used as a surrogate biomarker to report on ER function. As functional ER tran-
scribes the PR gene, the upregulation of PR is predictive of a functioning
estrogen-response pathway and therefore indicative of response to ER targeted endocrine
therapy. Furthermore, treatment response can be monitored by comparing basal and
post-treatment PR levels (Osborne et al., 1980). The poor representation of inter- and
intra-tumour heterogeneity from single biopsies can lead to inaccurate assessment of ER
status; furthermore, biopsy is not appropriate in the metastatic setting. As a consequence,
a clinical dilemma can present where equivocal response from ER/PR status may result in
inappropriate treatment planning. PET radiopharmaceuticals targeting SHRs exploit the
minimally invasive, highly sensitive and quantitative, whole-body imaging modality to
overcome the limitations of biopsy sampling. PET can be used as a predictive biomarker
for patient stratification and/or a therapy response biomarker for monitoring treatment;
in the case of breast cancer, both a predictive and therapy response marker are desirable
(Banerji and Workman, 2016, Mankoff et al., 2008). Clinical trials to image ER expression
with 16α-[18F]fluoro-17β-estradiol ([18F]FES) in primary and metastatic breast cancer
were promising (Fig. 1) (Allott et al., 2015, Mintun et al., 1988). [18F]FES has been used as
a predictive biomarker for stratifying patients to receive endocrine therapy (i.e. Tamoxi-
fen™, Fulvestrant™) and as a therapy response biomarker to identify patients who are not
responding to treatment. However, monitoring treatment response using [18F]FES, where
the ligand binding domain (LBD) of ER is saturated by a therapeutic dose of endocrine
Fig. 1 Structures of steroid hormone receptor radioligands: 16α-[18F]fluoro-17β-estradiol ([18F]FES), 21-
[18F]fluorofuranyl-norprogesterone ([18F]FFNP), [18F]fluoropropyl-Tanaproget ([18F]FPTP), [18F]fluoromethyl-
Tanaproget ([18F]FMTP) and [11C]Tanaproget. Substitutive nomenclature of benzoxazin(thi)one derivatives is
demonstrated using [18F]FMTP
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therapy agent, requires sufficient time for drug washout for post-treatment scans. There-
fore, [18F]FES is ideally suited for measuring pre-treatment target expression and drug oc-
cupancy of the receptor (Mankoff et al., 2017).
Imaging PR could potentially allow the monitoring of treatment response during endo-
crine therapy by reporting on ER function, providing an early indication of response
(Fowler et al., 2012). PR imaging has been evaluated using the steroidal PR ligand,
21-[18F]fluorofuranyl-norprogesterone ([18F]FFNP) in primary breast carcinoma as well as
reporting on treatment response in subsequent in vivo animal studies (Chan et al., 2015,
Dehdashti et al., 2012, Fowler et al., 2012). Although promising, 20-keto steroidal com-
pounds exhibit cross-reactivity with other SHRs (primarily the glucorticoid receptor, GR)
and are prone to metabolism by 20α-hydroxysteroid dehydrogenase (20-HSD).(Zhou et
al., 2010) The development of non-steroidal radiolabelled ligands based on the established
structure-activity relationship (SAR) of the benzoxazin(thi)one pharmacophore of the PR
agonist Tanaproget (Fig. 1) that exhibit high affinity and selectivity to PR while avoiding
20-HSD metabolism has also been explored (Fensome et al., 2005, Winneker et al., 2005,
Zhang et al., 2005, Zhang et al., 2002, Zhou et al., 2010).
Structural modification to the 1N-position (substitutive nomenclature described in
Fig. 1) of the benzoxazin(thi)one core interrupts an important hydrogen bond (Asn719)
formed in the LBD, whereas large substituents are tolerated at the C4-position
(Fensome et al., 2005, Zhou et al., 2010). Comparing the biological profile of oxo- and
thiocarbamates showed a “flip” effect between agonist and antagonist compounds.18
The modification of aryl moieties in the C6-position is tolerated and may improve
binding to the PR by establishing further hydrogen bonds, e.g. N-methyl-2-cyanopyr-
role of Tanaproget (Fensome et al., 2005).
The first example of a radiolabelled non-steroidal PR ligand was [18F]fluoropropyl-Ta-
naproget ([18F]FPTP, Fig. 1), which showed favourable biodistribution in the uterus of
immature estrogen-primed mice (Lee et al., 2010). Derivatising the gem-dimethyl at the
C4-position introduced a chiral centre into the molecule however, and the ligand was
evaluated as a racemic mixture. In silico evidence suggested that R- and S- enantiomers
may display different binding affinities and therefore further study would be required
to evaluate the enantiomerically pure species. [18F]Fluoromethyl-Tanaproget
([18F]FMTP) bears a fluoromethyl-substituent at the 1N-pyrrole position of Tanaproget
and was shown to maintain a high binding affinity to PR in accordance with
structure-activity relationship (SAR) data (Merchant et al., 2016). Larger substituents at
this position resulted in an inverse relationship between alkyl chain length and relative
binding affinity (RBA), limiting substitution to moieties no larger than a single methyl
group (Merchant et al., 2016, Zhou et al., 2010). [18F]FMTP was radiolabelled using the
[18F]fluoromethyltosylate prosthetic group and showed promising in vitro cell uptake
but poor in vivo metabolic stability. The development of novel radiochemistry method-
ology to access carbon-11 thiocarbamates allowed the synthesis of [11C]Tanaproget
from an acyclic precursor; however, in vitro cell studies were unsuccessful due to up-
take modulation by multi-drug resistance proteins (MDR) (Haywood et al., 2015,
Merchant et al., 2016). The poor performance of [11C]Tanaproget and the limited ex-
ploration of fluorine-18 radiolabelled non-steroidal PR ligands in the literature
prompted further investigation of suitable ligands for imaging PR with PET (Merchant
et al., 2016). Here we report the synthesis of a focused library of achiral, non-steroidal
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PR ligands which were evaluated in vitro for receptor binding. A lead candidate was se-
lected and radiolabelled with fluorine-18 and in vitro receptor binding, in vivo biodis-
tribution, imaging and metabolic stability was evaluated.
Methods
General
Reagents and solvents were purchased from Sigma-Aldrich (Gillingham, UK) and used
without further purification. Fluorobromomethane (2M in acetonitrile) was purchased
from ABCR (Karlsruhe, Germany). Nitrogen was used as an inert atmosphere for dry
reactions. 1H, 13C and 19F NMR spectra were obtained using a Bruker 500MHz spec-
trometer operating at room temperature. Chemical shifts (δ) are reported in parts per
million (ppm) and residual solvent peaks have been used as an internal reference. Peak
multiplicities have been abbreviated as follows: s (singlet), d (doublet), dd (doublet of
doublet), ddd (doublet of doublets of doublets), m (multiplet). Accurate mass spectros-
copy was carried out by Karl Heaton at The Department of Chemistry Mass Spectrom-
etry Service, University of York using a Bruker microTOF connected to an Agilent
1200 series LC system. Compound purity, radiochemical preparative RP-HPLC and
radio-RP-HPLC was carried out using an Agilent Infinity 1260 quaternary pump system
equipped with a 1260 diode array (Agilent Technologies, UK). HPLC methods appear
in the supporting information. [18F]Fluoride was produced via the 18O(p,n)18F reaction
using either a GE PETrace cyclotron by 16MeV irradiation, supplied by Alliance Med-
ical Radiopharmacy LTD (Warwick, UK) or using an ABT BG-75 mini cyclotron (ABT
Molecular Imaging, TN, USA) by 6.9MeV irradiation, supplied by The University of
Hull (Hull, UK). Pooled mouse liver microsomes (MLM) (20 mg/mL, female) for radio-
active MLM assays where purchased from Corning (Wiesbaden, Germany). Pooled
ICR/CD-1 mouse liver microsomes (MLM) (22 mg/ml, female, 400 donors) and human
liver microsomes (HLM) (24 mg/ml, mixed gender, 150 donors) for metabolite identifi-
cation assays were purchased from BioreclamationIVT (Frankfurt Am Main, Germany).
Chemical synthesis
The procedures for the synthesis of 6-bromo-4,4-dimethyl-1H-benzo[d][1,3]oxazin-2(4-
H)-one (1a), 2-(2-amino-5-bromophenyl)propan-2-ol (1b), (4,4-dimethyl-2-oxo-2,4-di-
hydro-1H-benzo[d][1,3]oxazin-6-yl)boronic acid (1c) and Tanaproget were followed
from the literature(Zhang et al., 2005). The Suzuki-coupling procedure reported in
Scheme 1a was adapted from the literature (Fensome et al., 2005).
6-(2-fluoropyridin-3-yl)-4,4-dimethyl-1H-benzo[d][1,3]oxazin-2(4H)-one (1).
Compound 1a (414 mg, 1.6 mmol) and Pd(PPh3)4 (47 mg, 0.04 mmol) were stirred in
toluene (8 mL) under an inert atmosphere. 6-Fluoropyridine-5-boronic acid (624 mg,
3.8 mmol) was dissolved in EtOH (8 mL) and added to the stirred flask, followed by
K2CO3 (436 mg, 3.1 mmol) dissolved in H2O (8 mL). The reaction mixture was de-
gassed and heated to 85 °C under an inert atmosphere for 16 h. The reaction was
cooled, quenched with sat. NaHCO3 (10 mL) and extracted with EtOAc (3 × 40mL).
Organic fractions were combined and washed with brine (100 mL), water (100 mL) and
dried over anhyd. MgSO4. Solvent was removed in vacuo, the product was isolated by
column chromatography (silica gel, 80% EtOAc / 20% hexane) as a white solid (22 mg,
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5%). 1H NMR (500MHz, CDCl3) δ 9.44 (s, 1H), 8.21 (ddd, J = 4.9, 1.9, 1.1 Hz, 1H), 7.86
(ddd, J = 9.7, 7.4, 2.0 Hz, 1H), 7.46 (dt, J = 8.2, 1.6 Hz, 1H), 7.37 (t, J = 1.7 Hz, 1H), 7.30
(ddd, J = 7.4, 4.8, 1.7 Hz, 1H), 7.02 (d, J = 8.2 Hz, 1H), 1.80 (s, 6H). 13C NMR (126MHz,
CDCl3) δ 161.21, 159.30, 152.92, 146.32, 140.29, 134.17, 130.53, 126.75, 123.83, 123.07,
121.91, 115.04, 83.05, 28.13. 19F NMR (471MHz, CDCl3) δ − 71.10. HRMS: calc’d for
C15H14FN2O2, 273.1034; found (ESI), 273.1025 [(M +H)
+].
2-(2-amino-5-(2-fluoropyridin-3-yl)phenyl)propan-2-ol (2b).
Compound 1b (200 mg, 0.9 mmol), (6-fluoropyridin-3-yl)boronic acid (147 mg, 1.0
mmol), Na2CO3 (184 mg, 1.7 mmol) and Pd(PPh3)2Cl2 were added to a microwave tube
and dissolved in degassed MeCN:H2O (1:1 v/v, 9 mL). The vessel was heated in a
microwave to 150 °C (200W) for 6 min. The reaction mixture was poured into water
(30 mL) and extracted with EtOAc (3 × 50mL). Organic fractions were combined and
dried over anhyd. MgSO4. Solvent was removed in vacuo and purified by column chro-
matography (silica, 40% EtOAc / 60% hexane) to give product as a brown solid (131
mg, 61%). 1H NMR (CDCl3, 400MHz) δ 8.10–8.11 (m, 1H), 7.80–7.83 (m, 1H), 7.36
(m, 1H), 7.31 (m, 1H), 7.21–7.24 (m, 1H), 6.72 (d, 1H, J = 8.4 Hz), 1.72 (s, 6H). 13C
NMR (CDCl3, 100MHz) δ 29.2, 74.1, 117.3, 121.7, 123.3, 126.3, 128.5, 130.4, 139.78,
144.6, 146.2, 159.1, 161.5. 19F NMR (CDCl3 400MHz) δ 71.25. HRMS: calc’d for
C14H16FN2O, 247.1241; found (ESI), 247.1239 [(M +H)
+].
6-(2-fluoropyridin-3-yl)-4,4-dimethyl-1H-benzo[d][1,3]oxazine-2(4H)-thione (2).
Compound 2a (250 mg, 1.0 mmol) and 1,1′-thiocarbonyldiimidazole (217 mg, 1.2
mmol) were stirred in dry THF (50 mL) at 50 °C under an inert atmosphere for 16 h.
Bulk solvent was removed in vacuo and the crude material was dissolved in EtOAc (50
mL) and washed with aqueous HCl (1M). Organic fractions were combined and dried
over anhyd. MgSO4. Solvent was removed in vacuo and the product was isolated by
column chromatography (silica, 40% EtOAc / 60% hexane) followed by precipitation
from ether to give product (65 mg, 22%). 1H NMR (500MHz, CDCl3) δ 9.67 (s, 1H),
8.24 (ddd, J = 4.9, 1.9, 1.2 Hz, 1H), 7.86 (ddd, J = 9.7, 7.4, 2.0 Hz, 1H), 7.51 (dt, J = 8.3,
1.6 Hz, 1H), 7.39 (t, J = 1.6 Hz, 1H), 7.32 (ddd, J = 7.4, 4.9, 1.7 Hz, 1H), 7.01 (d, J = 8.2
Hz, 1H), 1.83 (s, 6H). 13C NMR (126MHz, CDCl3) δ 184.17, 146.78, 146.66, 140.29,
131.37, 131.03, 129.59, 127.16, 123.89, 122.68, 121.98, 114.3, 84.81, 27.73. 19F NMR
(471MHz, CDCl3) δ − 70.96. HRMS: calc’d for C15H14FN2OS, 289.0805; found (ESI),
289.0800 [(M +H)+].
Scheme 1 a Synthesis towards PR ligands 1, 3, 5. Reaction conditions: (i) Pd(PPh3)4, K2CO3, EtOH, toluene,
aryl boronic acid, 85 °C, 16 h. b Synthesis of ligands 2, 4, 6. Reaction conditions: (ii) Pd(PPh3)2Cl2, Na2CO3,
MeCN:H2O (1:1), μW 150 °C, 6 min; (iii) TCDI, THF, 50 °C, 16 h
Allott et al. EJNMMI Radiopharmacy and Chemistry             (2019) 4:1 Page 5 of 20
6-(6-fluoropyridin-3-yl)-4,4-dimethyl-1H-benzo[d][1,3]oxazin-2(4H)-one (3).
Compound 3 was synthesised in a similar way to compound 1 in a 29% yield. 1H
NMR (500MHz, CDCl3) δ 9.03 (s, 1H), 8.39 (dt, J = 2.5, 0.8 Hz, 1H), 7.94 (ddd, J = 8.4,
7.5, 2.6 Hz, 1H), 7.43 (dd, J = 8.2, 2.0 Hz, 1H), 7.03 (ddd, J = 8.4, 3.1, 0.7 Hz, 1H), 7.00
(d, J = 8.2 Hz, 1H), 1.81 (s, 6H). 13C NMR (126MHz, CDCl3) δ 164.03, 162.13, 152.57,
145.55, 139.46, 135.55, 132.33, 127.74, 127.31, 122.00, 115.33, 109.56, 82.93, 28.10. 19F
NMR (471MHz, CDCl3) δ − 70.26. HRMS: calc’d for C15H14FN2O2, 273.1034; found
(ESI), 273.1025 [(M +H)+].
2-(2-amino-5-(6-fluoropyridin-3-yl)phenyl)propan-2-ol (4b).
Compound 4b was synthesised in a similar way to compound 2b in a 61% yield. 1H
NMR (CDCl3, 400MHz) δ 8.31 (d, 1H, J = 2.5 Hz), 7.85–7.90 (m, 1H), 7.28 (d, 1H, J =
2.2 Hz), 7.23 (d, 1H, J = 2.2 Hz), 6.95 (dd, 1H, J = 3.1, 8.6 Hz), 6.74 (d, 1H, J = 8.2 Hz),
1.73 (s, 6H). 13C NMR (CDCl3, 100MHz) δ 29.1, 73.7, 109.0, 117.5, 125.1, 125.2, 127.9,
131.2, 135.1, 143.0, 145.9, 160.9, 163.3. 19F NMR (CDCl3 400MHz) δ 72.64. HRMS:
calc’d for C14H16FN2O, 247.1241; found (ESI), 247.1235 [(M +H)
+].
6-(6-fluoropyridin-3-yl)-4,4-dimethyl-1H-benzo[d][1,3]oxazine-2(4H)-thione (4).
Compound 4 was synthesised in a similar way to compound 2 in a 19%. 1H NMR
(500MHz, CDCl3) δ 9.47 (s, 1H), 8.40 (dt, J = 2.7, 0.8 Hz, 1H), 7.94 (ddd, J = 8.5, 7.5,
2.6 Hz, 1H), 7.48 (dd, J = 8.2, 2.0 Hz, 1H), 7.31 (d, J = 2.0 Hz, 1H), 7.04 (ddd, J = 8.5, 3.1,
0.7 Hz, 1H), 6.99 (d, J = 8.2 Hz, 1H), 1.83 (s, 6H). 13C NMR (126MHz, CDCl3) δ
184.10, 145.66, 139.49, 134.06, 133.70, 131.31, 127.91, 127.67, 122.04, 114.66, 109.85,
109.55, 84.69, 27.69. 19F NMR (471MHz, CDCl3) δ − 69.63. HRMS: calc’d for
C15H14FN2OS, 289.0805; found (ESI), 289.0815 [(M +H)
+].
6-(3-chloro-4-fluorophenyl)-4,4-dimethyl-1H-benzo[d][1,3]oxazin-2(4H)-one (5).
Compound 5 was synthesised in a similar way to compound 1 in a 41% yield. 1H
NMR (500MHz, MeOD-d4) δ 7.72 (dd, J = 7.0, 2.4 Hz, 1H), 7.56 (ddd, J = 8.6, 4.5, 2.3
Hz, 1H), 7.52 (dd, J = 8.2, 2.0 Hz, 1H), 7.49 (d, J = 2.0 Hz, 1H), 7.31 (t, J = 8.9 Hz, 1H),
6.99 (d, J = 8.2 Hz, 1H), 1.75 (s, 6H). 13C NMR (126MHz, MeOD-d4) δ 167.95, 156.40,
152.63, 137.92, 134.15, 134.07, 128.40, 127.14, 126.57, 121.78, 120.77, 116.53, 114.61,
82.47, 26.79. 19F NMR (471MHz, MeOD-d4) δ − 120.80. HRMS: calc’d for
C16H14ClFNO2, 306.0692; found (ESI), 306.0692 [(M +H)+].
2-(4-amino-3′-chloro-4′-fluoro-[1,1′-biphenyl]-3-yl)propan-2-ol (6b).
Compound 6b was synthesised in a similar way to compound 2b in a 67% yield. 1H
NMR (400MHz, CDCl3) δ 7.49 (ddd, J = 7.0, 2.3, 0.8 Hz, 1H), 7.35–7.29 (m, 1H), 7.27–
7.24 (m, 1H), 7.21 (ddd, J = 8.1, 2.2, 0.8 Hz, 1H), 7.13 (td, J = 8.7, 0.7 Hz, 1H), 6.68 (dd,
J = 8.2, 0.7 Hz, 1H), 1.70 (s, 6H). 13C NMR (400MHz, CDCl3) δ 171.37, 158.22, 155.76,
145.70, 138.88, 130.99, 128.35, 126.85, 126.03, 124.50, 117.86, 116.72, 74.30, 29.44. 19F
NMR (500MHz, CDCl3) δ − 119.80. HRMS: calc’d for C15H16ClFNO, 280.0899; found
(ESI), 280.0898 [(M +H)+].
6-(3-chloro-4-fluorophenyl)-4,4-dimethyl-1H-benzo[d][1,3]oxazine-2(4H)-thione (6).
Compound 6 was synthesised in a similar way to compound 2 in a yield of
30%. 1H NMR (500 MHz, CDCl3) δ 9.62 (s, 1H), 7.56 (dd, J = 6.9, 2.3 Hz, 1H),
7.45 (dd, J = 8.2, 2.0 Hz, 1H), 7.39 (ddd, J = 8.5, 4.5, 2.3 Hz, 1H), 7.29 (d, J = 1.9
Hz, 1H), 7.23 (t, J = 8.6 Hz, 1H), 6.97 (d, J = 8.2 Hz, 1H), 1.83 (s, 6H). 13C NMR
(126 MHz, CDCl3) δ 184.05, 158.82, 156.83, 137.20, 136.45, 130.96, 129.01,
127.78, 127.41, 126.54, 123.26, 117.05, 114.53, 84.79, 27.74. 19F NMR (471 MHz,
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CDCl3) δ − 117.17. HRMS: calc’d for C16H14ClFNOS, 322.0463; found (ESI),
322.0459 [(M + H)+].
4,4-dimethyl-6-(2-nitropyridin-3-yl)-1H-benzo[d][1,3]oxazin-2(4H)-one (7).
Compound 1c (200 mg, 0.90 mmol), 2-nitro-3-bromopyridine (164 mg, 0.80 mmol),
K2CO3 (226 mg, 1.63 mmol) and Pd(PPh3)2Cl2 (28 mg, 0.04 mmol) were added to a
microwave tube (10 mL) and dissolved in degassed MeCN:H2O (1:1, 7 mL). The vessel
was heated in the microwave (150 °C, 200W) for 20 min. The reaction mixture was
allowed to cool, poured into water (30 mL) and extracted with EtOAc (3 × 50mL). Or-
ganic fractions were combined and dried over anhyd. MgSO4. Solvent was removed in
vacuo and product was isolated by column chromatography (silica, 80% EtOAc / 20%
hexane) as a beige solid (130 mg, 48%). 1H NMR (500MHz, CDCl3) δ 8.64 (s, 1H), 8.54
(dd, J = 4.7, 1.7 Hz, 1H), 7.93 (dd, J = 7.7, 1.7 Hz, 1H), 7.66 (dd, J = 7.7, 4.7 Hz, 1H), 7.26
(dd, J = 2.0 Hz, 1H), 7.14 (d, J = 2.0 Hz, 1H), 6.96 (d, J = 8.2 Hz, 1H), 1.76 (s, 6H). 13C
NMR (126MHz, CDCl3) δ 157.63, 152.08, 150.04, 147.46, 141.06, 134.84, 129.49,
129.15, 128.74, 127.21, 127.16, 123.10, 115.14, 82.83, 28.01.
Radiosynthesis of [18F]2
To a Wheaton vial was added a mixture of K2CO3 (0.1M, 100 μL), Kryptofix™ K222 (3
mg), acetonitrile (200 μL) and [18F]fluoride (1.5–1.7 GBq in 200–300 μL 18O-water).
The solvent was removed by azeotropic distillation at 110 °C under a stream of nitrogen
with three repeat additions of acetonitrile (300 μL) until dry. A solution of precursor 7
(1 mg, dissolved in 300 μL dry DMSO) was added to the vial and heated at 160 °C for
15 min. An aliquot (2 μL) was taken for RP-HPLC analysis (Additional file 1: Figure
S28) using gradient 2 (supporting information, section 5). The reaction mixture was
added to water (10 mL) and immobilized on a Sep Pak C18 light cartridge (pre-condi-
tioned with MeOH (5 mL) and water (10 mL)). The cartridge was washed with water
(5 mL) to remove residual [18F]fluoride and [18F]1 was eluted with MeOH (700–
1000 μL) into a clean Wheaton vial. The MeOH was removed by evaporation under a
stream of nitrogen (ca 5 min) until a residue remained. Lawessons reagent (15 mg) was
added to dry residue followed by toluene (300 μL). The vial was sealed tightly and
heated to 135 °C for 35 min. The toluene was evaporated under a stream of nitrogen
(ca 5 min) and the reaction mixture was reconstituted into DMSO (400 μL). An aliquot
(5 μL) was taken for RP-HPLC analysis (Additional file 1: Figure S29) using gradient 3
(supporting information, section 5). The reaction mixture was filtered and purified
using preparative RP-HPLC. The cut peak was diluted in water (10 mL) and immobi-
lized on a HLB cartridge (10 cc), pre-conditioned with EtOH (5 mL) and water (10 mL).
The immobilized product was washed with water (5 mL) and eluted with EtOH
(400 μL) into a clean vial. The EtOH was evaporated to ~ 30 μL volume and diluted
with PBS to give a final solvent composition of 10% EtOH/PBS for biological use. An
aliquot (20 μL) was taken for RP-HPLC analysis (Additional file 1: Figures S9 - S10).
Distribution coefficient analysis (LogD7.4)
Radioligand [18F]2 (0.03MBq, 1 μL, in EtOH) was mixed with PBS (500 μL) and n-octa-
nol (500 μL). The sample was vortexed (10 min) followed by centrifugation (1×g, 10
min). Three aliquots (100 μL) from each layer were taken and counts measured using a
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2480 WIZARD2 Automatic Gamma Counter (PerkinElmer, UK). Experiment was re-
peated in triplicate in n = 3 determinations (supporting information, Additional file 1:
Table S1). Distribution coefficient (LogD7.4) was calculated as the logarithm of the ratio
between CPM of the octanol and buffer phase.
T47D potency studies
The method described by Di Lorenzo et al was followed with minor adaptation (Di Lor-
enzo et al., 1991). In brief, T47D breast carcinoma cells were seeded in 96-well plates at
50,000 cell/well in RPMI medium supplemented with 10% FBS. After overnight culture,
the medium was changed to RPMI phenol red free containing 2% charcoal-stripped
FBS. After 24 h, the cells were treated with progesterone (Sigma Aldrich, Gillingham,
UK) or the library compounds. Progesterone and the test compounds were dissolved in
DMSO (100%) and diluted into treatment medium to give a final DMSO (v/v) concen-
tration of 0.1%. After incubation (48 h) the treatment was finalised by twice washing
the plates with PBS. Cells were lysed by two freeze-thaw cycles (− 80 °C). Cellular alka-
line phosphatase activity was determined by adding Femto ELISA-AP substrate
(200 μL) and optical density measurements taken at 5 and 10 min intervals at a wave-
length of 405 nm. Data was interpreted using Graphpad Prism (GraphPad, CA, USA)
using the model: dose-response simulation/inhibition, log(agonist/inhibition) vs. re-
sponse – variable slope (four parameters). For compounds where EC50 > 10,000, an an-
tagonist profile was assumed and the experiment was repeated with the inclusion of
progesterone (3 mM) with the library compound. Data shown in the supporting infor-
mation (Additional file 1: Figure S32).
GR nuclear translocation assay
Compound 2 was analysed for GR binding using the PatHunter® express CHO-K1 GR
Nuclear Translocation assay (DiscoveRx™, Fremont, CA, USA). Reagents were thawed
and equilibrated to room temperature prior to use. Dexamethasone standard (10 mM,
100% DMSO) was diluted and used to prepare 12 standards by 1:4 dilution. Test com-
pound 2 was dissolved in 100% DMSO and diluted in serial 1:3 dilutions to a final con-
centration of DMSO (v/v) of 0.1%. CHO-K1 (Chinese hamster ovary) cells were seeded
in a 96-well plate with CP reagent and incubated for 24 h at 37 °C, 5% CO2. Cells were
then incubated with the Dexamethasone standard and compound 2 for 6 h at 37 °C, 5%
CO2. Following incubation, signal was detected using the PathHunter® detection re-
agent provided in the kit and incubated in the dark for 1 h. The plate was read using a
luminescence plate reader (Additional file 1: Figure S33).
Immunoblotting
Protein samples were analysed by sodium dodecyl sulfate-polyacrylamide (SDS-PAGE)
gel followed by Western blotting. Equal amount of proteins per sample (50–100 μg)
was resolved on a 10%–12% SDS-PAGE. Molecular weight ladders (Precision Plus Pro-
tein Western C Standard, BioRad, CA, USA) were loaded together with the samples.
Electrophoresis was performed at 100-120 V for 1.5 h. When the migration front
reached the bottom of the gel, electrophoresis was stopped and proteins were trans-
ferred onto a 0.45-μm PVDF membrane (polyvinylidene difluoride) previously activated
Allott et al. EJNMMI Radiopharmacy and Chemistry             (2019) 4:1 Page 8 of 20
in methanol for 2 min. The transfer was performed for 1 h at 100 V in 1× blotting buf-
fer containing 20% methanol. The PVDF membrane was blocked for 1 h in a milk solu-
tion (5% fat-free powdered milk in 0.1% PBST and 0.1% Tween) and rinsed thoroughly
in 0.1% PBST. The membrane was incubated overnight at 4 °C with the primary anti-
body (PR antibody from Cell Signalling) in a 1:1000 dilution in 5% milk-0.1% PBST.
Membrane was washed 3 times (5 min/wash) in 0.1% PBST and incubated 1 h at room
temperature with the appropriate secondary antibody (anti-rabbit IgG 1:2000 dilution).
The membrane was washed 3 more times in 0.1% PBST, and incubated with 1 mL of
reagent mixture (1:1) form the Amersham enhanced chemiluminescence (ECL) Plus
Western Blotting Detection kit (GE Healthcare) and imaged using the ChemiDoc XRS
+ System and the Image Lab software (BioRad, CA, USA).
Cell uptake study
T47D, MCF-7 and MDA-MB-231 cells (1 × 105) were plated into 6-well plates and used
for receptor binding assays at 60–80% confluence. Cell medium was removed and cells
were washed with cold PBS buffer. [18F]2 (37 kBq/mL) was added to individual wells
and cells were incubated at 37 °C in a humidified atmosphere of 5% CO2 for 60 min.
Cells were co-incubated with 0.01–1 μM of cold progesterone for the blocking study.
Cells were then washed 3 times with ice-cold PBS and lysed with RIPA buffer. Radio-
activity was determined using a gamma spectrometer (Automatic Gamma counter,
Wizard 3 Wallac). Radioactivity was normalised to protein content determined using a
BCA 96-well plate assay (Thermo Fisher Scientific Inc., USA) and expressed as a per-
centage of total radioactivity per mg of protein.
Mouse model
Pubertal female C57BL/6 mice were injected intraperitoneally with 30 IU gonadotro-
pins, 15 IU Follicle-stimulating hormone (FSH) and 15 IU luteinizing hormone (LH)
followed by 5 IU menotropin (hCG) after 48 h (Sigma-Aldrich, Gillingham, UK). After
the imaging studies, the ovaries were removed and snap-frozen in liquid nitrogen for
later analysis of protein expression by western blot.
Biodistribution
[18F]2 (455 ± 62 kBq) was injected into the tail vail of female C57BL/6 mice. Whilst under
anaesthesia the animals were sacrificed and tissues of interest such as, heart, lung, liver,
spleen, kidneys, stomach, muscle, bone, ovary, small intestines and large intestines were
collected in pre-weighed counting tubes. Radioactivity within tissue samples was counted
in a gamma spectrometer (Automatic Gamma Counter, Wizard 3 Wallac), and then
weighed to determine the mass of the tissue. CPM for each tissue sample was normalised
to the total injected dose of radioactivity to the animal to give %ID (injected dose), and
then normalised to the weight of the counted tissue to give the radioactivity uptake of the
tissue as %ID/g. Tabulated values shown in Additional file 1: Table S2.
PET/CT imaging
Mice were anaesthetised with 3–5% isoflurane at a flow rate of 1 L/min, and then re-
duced to 1.5–2% isoflurane for anaesthesia maintenance during imaging. [18F]2 was
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injected via the tail vein at the commencement of a dynamic PET scan using a dedi-
cated small animal PET/CT scanner (Sedecal SuperArgus2R, Sedecal, Spain). Images
were acquired over a 50 min imaging sequence, followed by CT imaging acquired in
514 projections for anatomic coregistration. PET emission data were corrected for
decay and dead time and reconstructed using 3D-OSEM. Data were analysed based on
regions of interest (ROI) drawn within the tumours and tissue. Time-activity curves
(TAC) were calculated as an average form the region of interest analysis of three mice
(Additional file 1: Figure S34). Data was analysed using AMIDE software (Loening and
Gambhir, 2003) and VivoQuant (InVicro, MA, USA) and regions of interest (ROIs)
were selected by hand, and the count densities were averaged for each frame to obtain
a TAC for each ROI.
In vitro radioactive metabolite analysis of [18F]2
Radioligand [18F]2 (3 MBq, ca. 80 μL), mouse liver microsomes (50 μL, 1 mg/mL),
NADPH regeneration system A (50 μL), NADPH regeneration system B (10 μL), PBS
0.5M pH 7.5 (200 μL) and water (ca. 200 μL) were added to a plastic 1.5 mL tube. The
mixture was incubated at 37 °C for 60 min and transferred into a plastic centrifuge tube
(10 mL). Proteins were precipitated with ice-cold MeOH (2 mL) and the mixture was
centrifuged (12,000 g, 3 min) to pellet the precipitate. The supernatant was removed,
evaporated to dryness and the residue was suspended in 37% MeCN + 0.1%TFA / 63%
Water + 0.1%TFA for RP-HPLC using gradient 3 (supporting information, section
10.3). The experiment was performed in n = 3 determinations. Extraction efficiency of
radioactivity from the protein pellet was calculated to be 93.5% ± 1.6 (Additional file 1:
Table S3). HPLC data is shown in the supporting information (Additional file 1: Figure
S35).
In vitro non-radioactive metabolite analysis of 2
Microsomal incubations were performed using a Hamilton Microlab Star liquid hand-
ling workstation (Hamilton Robotics, Bonaduz, Switzerland). Test compound 2 (final
concentration 1 or 10 μM, 1% DMSO) was pre-incubated at 37 °C for 10 min in MLM
or HLM (final concentration 1 mg/ml prepared in 10mM PBS). Reactions were initi-
ated by the addition of NADPH (final concentration 1 mM). Aliquots were removed
from each incubation and quenched in 3 volumes of ice-cold MeOH containing in-
ternal standard olomoucine (500 nM in MeOH) at − 1, 0, 5, 15, 30 and 60min. Incuba-
tions were conducted in singlicate. Inactive control incubations (without NADPH)
were conducted in parallel. Terminated incubations were centrifuged at 3700 rpm at 4 °
C for 30 min and supernatant taken for analysis. Microsomal incubations were analysed
by liquid chromatography-tandem mass spectrometry (LC-MS/MS). This consisted of a
Dionex Ultimate 3000 UHPLC system coupled to a ThermoScientific Q Exactive Plus
orbitrap mass spectrometer (Thermo Fisher Scientific Inc., Waltham, USA). Chromato-
graphic separation was achieved using an Acquity UPLC HSS T3 column (1.8 μm,
100 × 2.1 mm) (Waters, Elstree, UK) at 50 °C and a binary mobile phase gradient at a
flow rate of 0.4 ml/min. Initial LC conditions comprised 10% formic acid (0.1%) in
water (A), 90% methanol (B). This was ramped to 95% A at 12 min. Sample analysis
was by positive ion electrospray ionization. The capillary voltage was 3.5 kV. Full MS/
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dd-MS2 (full MS scan followed by data dependent MS/MS) and Full MS/AIF (full MS
scan followed by all ion fragmentation) workflows were used in combination. Full MS
was performed at a resolution of 70,000, AGC target 1 e6; dd-MS2 at a resolution of
17,5000, AGC target 1 e5. LC-MS response (peak area of the analyte/peak area of in-
ternal standard) was fitted to a nonlinear single exponential model using software
GraphPad Prism software (v6.07, GraphPad Software, Inc., La Jolla, USA). Elimination
rate constant (k) was determined and intrinsic clearance, CLint, was calculated as CLint
= (V.k)/mg protein where V is the incubation volume (μl) and mg protein is the mg
microsomal protein in the incubation. Identification of metabolites in microsomal incu-
bations and elucidation of their structures was undertaken with Compound Discoverer
software (v2.0.0.303, Thermo Fisher Scientific Inc., Waltham, USA).
Results
Chemistry
A focused library of benzoxazin(thi)one compounds (Fig. 2) was synthesised using two
routes: Route A (Scheme 1a), where benzoxazinone compounds were synthesised from
aryl-bromide 1a using palladium catalysed Suzuki-coupling chemistry with commer-
cially available fluorine-substituted boronic acids; compounds 1, 3 and 5 were accessed
in ca 18% yield. Benzoxazinthione compounds were synthesised using Route B (Scheme
1b), an “acyclic approach” employing a Suzuki-coupling reaction with aryl-bromide 1b
and fluoro-aryl boronic acids to form biaryl “acyclic compounds” (2b, 4b, 6b) in ca
63% yield. Subsequent installation of the thiocarbamate using 1,1′-thiocarbonyldiimida-
zole (TCDI) yielded compounds 2, 4 and 6 in an overall yield of ca 18%. Compounds
were characterised by 1H/13C/19F-NMR (Additional file 1: Figures S1 S20), HRMS and
compound purity was > 95% by RP-HPLC (Additional file 1: Figures S21 S27).
Fig. 2 Focused library of PR ligands (1–6)
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In vitro potency assay
Compounds (1–6) were evaluated in an T47D alkaline phosphatase (AP) assay to iden-
tify a lead candidate for further evaluation (Table 1). Tanaproget was included as a posi-
tive control and the EC50 was comparable with the literature (T47D EC50 = 0.15 nM)
(Fensome et al., 2005).
Radiochemistry
The nitro-containing precursor (7) was synthesised by conversion of 1a into a boronic
acid 1c followed by palladium catalysed Suzuki-coupling with 3-bromo-2-nitropyridine
(Additional file 1: Figure S1). The radiolabelling of [18F]2 was achieved by [18F]fluoride
incorporation into precursor (7) with K[18F]fluoride/K2.2.2 and K2CO3 to yield [
18F]1
followed by conversion to the thiocarbamate ([18F]2) using Lawessons reagent
(Scheme 2); average [18F]fluoride incorporation into [18F]1 was 60.9 ± 14.1% (n = 5)
after 15 min. Solvent was exchanged from DMSO to toluene, assisted by C-18
solid-phase extraction (SPE), followed by the addition of Lawessons reagent to convert
the intermediate [18F]1 into the desired thiocarbamate [18F]2, with an efficiency of
43.9 ± 23.1% (n = 5, Additional file 1: Figure S9). Compound [18F]2 was isolated by pre-
parative RP-HPLC and reformulated using HLB-SPE into 10% (v/v) EtOH/PBS for bio-
logical evaluation with a molar activity of 2.5 ± 1.6 GBq/μmol (mean ± SD) and a
radiochemical purity ≥95%. The identity of [18F]2 was confirmed by HPLC co-elution
with an authentic sample of compound 2 (Additional file 1: Figure S30). The radio-
chemical yield (decay-corrected to the start of synthesis) was 2.29 ± 2.31% (n = 6)
with a synthesis time of 167 min (n = 6). Radioligand [18F]2 was 99.7% stable up to
4 h after formulation. The distribution coefficient (LogD7.4) was determined by par-
titioning [18F]2 between PBS (pH 7.4) and octan-1-ol and was calculated to be
1.69 ± 0.1 (Additional file 1: Table S1).
In vitro cell uptake assay
The uptake of [18F]2 was evaluated in a panel of three breast cancer cell lines with
varying PR expression, determined by Western Blot analysis (T47D = PR++, MCF-7 =
PR+ and MDA-MB-231 = PR-, Fig. 3a). Radioligand [18F]2 showed significant accumu-
lation in T47D cells (PR++) compared to MCF7 (PR+) and MDA-MB-231 (PR-) cells,
Table 1 Potency of 1–6 in a T47D alkaline phosphatase assays, including Tanaproget (TNP) as a
reference compound
compd cLogPc T47D alkaline phosphatase assay EC50 (nM)
a T47D alkaline phosphatase assay IC50 (nM)
a
TNP 4.16 0.5 –
1 2.98 > 10,000b 844.8 ± 0.23
2 4.17 4.7 ± 0.07 –
3 2.98 > 10,000b 795.0 ± 0.25
4 4.17 3674.0 ± 0.08 –
5 5.02 2294.0 ± 0.29 –
6 6.18 432.5 ± 0.24 –
aExperimental values for 1–6 are presented as an average of at least n = 3 measurements ± standard deviation (SD).b The
EC50 of 1 and 3 showed no agonist activity so IC50 values were calculated from the inhibition of progesterone (3 mM).
c
Calculated log P o/w from Chemdraw 12.0
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suggesting a PR-mediated uptake (Fig. 3b). The uptake was confirmed to be specific in
T47D cells by co-incubating [18F]2 with progesterone (0.01–0.1 μM). The uptake of
[18F]2 decreased in a dose-dependent manner (Fig. 3c) which confirmed that [18F]2
was occupying the LBD of PR.
In vivo biodistribution
The in vivo biodistribution of [18F]2 was evaluated in C57BL/6 female mice receiv-
ing a dose of gonadotropins (15 IU FSH + 15 IU LH) plus 5 IU hCG, 48 and 6 h to
induce PR expression in the ovary; PR was not induced in the control mice (Figs. 4
and 5). The upregulation of PR was confirmed by ex vivo western blot analysis
after the imaging study (Fig. 3a). Biodistribution analysis at 50 min showed a
non-significant increase in uptake of [18F]2 in the ovary of the control animals
(1.32 ± 0.22 %ID/g) and GH stimulated animals (2.17 ± 0.03 %ID/g); however, more
notable was the large accumulation of radioactivity in bone and small intestine in
both cohorts of mice.
Scheme 2 Radiosynthesis of [18F]2; Reaction conditions: (i) K[18F]fluoride/K2.2.2, K2CO3, DMSO, 160 °C 15 min;
(ii) Lawessons reagent (15 mg), toluene, 135 °C, 35 min
Fig. 3 In vitro characterisation of [18F]2 in breast cancer cell lines with varying PR expression levels. a
Western Blot showing PR expression in cell lines and in ovarian of C57BL/6 female mice with or without
gonadotropic stimulation of PR expression (+/− HT). b Uptake of [18F]2 in three cell lines. c Blocking [18F]2
uptake in T47D cells treated with progesterone (0.01–1 μM). Error bars indicate standard errors from n = 3
repeats. Significances are marked with asterisk, (*) and (**) P ≤ 0.05, P ≤ 0.01, respectively
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Metabolite analysis
The rapid in vivo defluorination of [18F]2 was surprising as similar 2-fluoropyridine
compounds are reported to be metabolically stable; to evaluate this further in vitro me-
tabolite analysis using mouse liver microsomes (MLM) was performed to inform future
radioligand development.(Bouvet et al., 2016, Mccarron et al., 2004) Polar metabolites
were observed after incubating [18F]2 with MLM for 60min (4.4%, Rt = 2:00–5:00
Fig. 4 Biodistribution analysis of selected tissues from C57BL/6 female mice injected with [18F]2 and
sacrificed at 50 min post-injection. A group of four animals received a dose of gonadotropins (15 IU FSH +
15 IU LH) plus 5 IU hCG, 48 and 6 h, respectively, before the imaging studies. All radioactivity values were
converted in %ID/g of tissue. Biodistribution data are means of ± SEM of three to four animals. LI = large
intestine, SI = small intestine. Tabulated values shown in Additional file 1: Table S2
Fig. 5 Representative coronal (a) and sagittal (b) PET/CT images of [18F]2 in C57BL/6 female mice at 50 min
p.i. White arrows indicate the bone (i), liver (ii), small intestine (iii) and muscle (iv). Extensive skeletal uptake
of [18F]2 is indicative of defluorination
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min:sec) however, the major metabolite (63 ± 1.9%) was a single peak at ca tR = 7:05
(Fig. 6). The retention time of this metabolite corresponded with that of compound 1,
the oxocarbamate derivative of 2, therefore it was speculated that oxidative metabolism
converted [18F]2 into [18F]1. This metabolic pathway has been previously described for
Tanaproget and the conversion may be facilitated through an S-linked glucuronide
intermediate (Keating et al., 2006). The conversion was confirmed by repeating the ex-
periment and spiking the parent [18F]2 with an aliquot of [18F]1 (Additional file 1: Fig-
ure S36). Spectral analysis of the metabolite was confounded by the low mass of
material required to obey the tracer dose principle; therefore, the experiment was re-
peated on a macroscopic scale by incubating compound 2 with MLM and human liver
microsomes (HLM). Metabolites were identified by mass spectrometry and drug clear-
ance was evaluated. Metabolite identification confirmed the conversion of the thiocar-
bamate into oxocarbamate as the major metabolic pathway and highlighted oxidative
defluorination of 2 in both MLM and HLM (Additional file 1: Tables S5 and S6). Un-
fortunately, the exact structure of the oxidised and defluorinated metabolite could not
be resolved from the mass spectra although we propose that an initial oxidation may fa-
cilitate the defluorination. Compound 2 was cleared rapidly from MLM at a rate of
1270 μL/min/mg protein and ca. 22-fold slower in HLM (56 μL/min/mg protein), sug-
gesting that the rapid metabolism of 2 may be species dependent; however, defluorina-
tion was evident in both MLM and HLM, therefore it is unlikely that the fate of [18F]2
would be different in humans, especially at the sub-nanomolar quantities of [18F]2
present in a tracer dose. We also performed in vitro metabolite analysis of compound 1
Fig. 6 Representative analytical RP-HPLC chromatograms of: a parent compound [18F]2; b analysis after
incubation of [18F]2 with MLM for 60min
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in MLM and HLM to determine if defluorination was independent of the presence of
the thiocarbamate; compound 1 showed defluorinated species in both MLM and HLM
experiments with a comparable clearance. The presence of a defluorinated metabolite
in MLM corroborates the rapid in vivo defluorination of [18F]2.
Discussion
The synthesis of a focused library of PR ligands was guided by the SAR of Tanaproget
and other benzoxazin(thi)one derivatives. Five design criteria were proposed to struc-
ture the synthetic strategy which yielded the focused library described in Fig. 2:
i) The ligand must contain a fluoro-aryl substituent to facilitate fluorine-18
radiochemistry;
ii) Structural diversity through derivatisation of the 6-aryl position;
iii) Preference for achiral compounds to avoid requirement for chiral purity during
radiochemistry steps and formulation;
iv) Ligands may contain a cyclic carbamate or thiocarbamate;
v) Ligands should exhibit a cLogP < 5 to limit non-specific binding.
Modifying the substituent at the 6-aryl position created a library of structurally di-
verse, fluorine-containing compounds. For each compound, the oxocarbamate and
thiocarbamate derivative was synthesised to evaluate the effect of carbonyl and thiocar-
bonyl moieties on potency. An advantage of our synthetic methodology was the poten-
tial for intermediates 2b, 4b and 6b to be radiolabelled with carbon-11 using a
[11C]CS2 methodology previously reported for the radiosynthesis of [
11C]Tanaproget
(Haywood et al., 2015).
In the potency assay comparison between oxo- and thiocarbamate compounds
showed the “flip” between agonist and antagonist profiles in agreement with the litera-
ture (Table 1) (Fensome et al., 2005). Compounds 1 and 3 were predicted to be the
least lipophilic compounds in the library; however they did not induce an agonist re-
sponse within the assay parameters (EC50 < 10,000 nM), suggesting a stronger antagon-
ist profile. The ability to bind PR was confirmed by competition with progesterone (3
mM); 1 and 3 exhibited low micromolar antagonist activity (844.8 ± 0.23 and 795.0 ±
0.25 nM respectively). Compound 6 was ca 5-fold more potent (EC50 = 432.5 ± 0.24
nM) than the corresponding oxocarbamate derivative 5 (EC50 = 2294 ± 0.29); with
cLogP values ≥5 and low micromolar potency, these compounds did not meet the re-
quired characteristics for evaluation as PR imaging agents. The most potent compound
in the library was 2 (EC50 = 4.7 ± 0.07 nM) and was predicted to exhibit a similar lipo-
philicity to Tanaproget. The binding specificity of compound 2 was evaluated in a GR
nuclear translocation assay using CHO-K1 cells and failed to elicit a response at
0.5 μM, suggesting little cross-reactivity (Additional file 1: Figure S33). The failure to
elicit a response in the GR nuclear translocation assay provided confidence that 2 was
specific to PR without evaluating the full SHR family. Confidence in extrapolating
cross-reactivity to the whole SHR family based upon GR alone came from the high de-
gree of homology between SHRs and the extensive investigation into the
cross-reactivity of benzoxazin(thi)one derivatives in the literature.
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It is not clear why 2 exhibited greater potency compared to structural isomer 4 (ca
1000-fold more potent). The crystal structure of Tanaproget bound to PR demonstrates
that the nitrile group forms important hydrogen bonds with the Gln725 and Arg766
amino acid residues (distance of 3 and 2.6 Å respectively) (Zhang et al., 2005). The pyri-
dine moiety of 2 and 4 is also a potential hydrogen bond acceptor with one (or both) of
the residues. Three-dimensional models of Tanaproget and 2 were overlaid and aligned
at the benzoxazinthione pharmacophore, the aryl moiety in the C6-position of both
molecules was rotated and brought the nitrile of Tanaproget (Fig. 7, blue arrow) and
the nitrogen of the pyridine (Fig. 7, red arrow) in compound 2 into close proximity in
space providing tentative evidence that 2 may be capable of forming hydrogen bonds
with the same residues as Tanaproget. We propose that the 6-fluoro substitution in
compound 4 sterically forces the molecule to adopt a binding pose in the LBD that is
unfavourable for hydrogen bonding. The 2-fluoro substitution of compound 2 does not
perturb a favourable binding pose and the formation of hydrogen bonds, which
accounted for the low nanomolar potency of 2.
Compound 2 was radiolabelled using nucleophilic heteroaromatic substitution (SNAr)
at the 2-position of the pyridine ring by displacement of a nitro leaving group without
the necessity of an electron-withdrawing substituent (Scheme 2) (Dolle, 2005). Further-
more, the 2-fluoropyridin-3-yl moiety in compound 2 presented the opportunity to
utilise well-established SNAr radiochemistry to access an intermediate radiolabelled
pyridine. Consistent with the radiosynthesis of [18F]FPTP and our preliminary studies,
direct radiolabelling of a thiocarbamate precursor did not yield [18F]2, likely due to the
increased nucleophilicity of the thiocarbonyl compared to oxocarbonyl (data not
shown). Conversion to the thiocarbamate was required post-radiolabelling as exempli-
fied in the radiosynthesis of [18F]FPTP (Lee et al., 2010).
Biodistribution in hormone stimulated female mice (Fig. 4) showed uptake of radio-
activity in the bone was 2-fold higher in the GH stimulated mice (31.21 ± 5.99 %ID/g)
compared to the control group (15.36 ± 3.50 %ID/g); growth hormones are known to
induce the expression of metabolic enzymes in the liver, therefore an increase in radio-
activity uptake in the bone is suggestive of metabolic defluorination of [18F]2 (Waxman
and Holloway, 2009). PET images acquired over 50 min showed an accumulation of
radioactivity in the liver and small intestines, but also in the spine, joints and skull (Fig.
Fig. 7 A three-dimensional representation of Tanaproget and compound 2, overlaid at the benzoxazinthione
pharmacophore: a side-view; b top-down view; red arrow: nitrogen of the pyridine moiety of 2; blue arrow:
nitrogen of the nitrile moiety of Tanaproget
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5 and movie in ESI). Time activity curves acquired over the dynamic scan showed rapid
accumulation of radioactivity in the small intestine with an increase in bone uptake
over time, indicative of radioligand defluorination (Additional file 1: Figure S34). The
poor in vivo stability of [18F]2 did not warrant further investigation into alternative pre-
clinical animal models. The metabolic oxidation of the benzoxazinthione pharmaco-
phore to the corresponding oxocarbamate has not been reported previously in the
context of radioligand development and represents an important finding for the future
development of PET radioligands derived from this pharmacophore. Furthermore, we
present an example of a metabolically unstable 2-[18F]fluoropyridine moiety, previously
assumed to be resistant to in vivo defluorination based upon the current literature.
Conclusions
The synthesis and biological evaluation of a focused library of non-steroidal PR ligands
for PET imaging highlighted compound 2 as a candidate for further biological evalu-
ation. A radiosynthetic route to access [18F]2 was developed to allow in vitro and in
vivo evaluation. Radioligand [18F]2 demonstrated significant in vitro uptake in PR++
T47D cells which could be blocked in a dose dependent manner with progesterone.
However, [18F]2 showed poor in vivo metabolic stability with rapid defluorination
within the time frame of the imaging protocol. In vitro metabolite analysis of 2 in
MLM confirmed defluorination and oxidative metabolism of the thiocarbamate to oxo-
carbamate moiety by mass spectrometry. In summary, [18F]2 has inadequate stability
for in vivo imaging in mice and with a similar metabolic profile in HLM, is predicted
to be unsuitable for use in humans. The future development of PR imaging agents
based around the benzoxazinthione pharmacophore should proceed with caution due
to the described metabolic conversion into the benzoxazinone derivative. In addition,
we have shown that 2-[18F]fluoropyridine moieties should not be assumed to be meta-
bolically stable to defluorination. In a scenario where [18F]2 was stable to defluorina-
tion, conversion from the thiocarbamate into the oxocarbamate may change the
properties of the ligand such as receptor affinity which could confound in vivo evalu-
ation. The development of metabolically stable non-steroidal imaging agents targeting
PR is ongoing.
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